Damora Therapeutics (DMRA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$31.2M

Net income growth (year over year)

−807.01%

Net margin

—

Return on equity

−100.00%

EPS (trailing twelve months)

$7.70

Book value per share

$6.25

P/E (trailing twelve months)

—

Price to book

2.15

Debt to assets

5.07%

Payout ratio

—

Dividend yield

—

Company profile

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

• How do I buy stock in Damora Therapeutics (DMRA)?

  DMRA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.